Basic Information
N-Gene is a clinical-stage biopharmaceutical developer dedicated to the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs utilize the proprietary synthetic small molecule BGP-15, which has proven effective in various indications related to adverse metabolic conditions, including type 2 diabetes caused by blocking JNK phosphorylation, and exhibits novel therapeutic effects by modulating stress responses. This enables pharmaceutical companies to access a range of synthetic molecules that can treat insulin resistance syndrome, enhance cancer chemotherapy, and delay skin aging.